Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.
Amedisys Inc. (NASDAQ: AMED) is a leading healthcare services company in the United States, specializing in delivering personalized home health, hospice, and high-acuity care services. Headquartered in Baton Rouge, LA, with an executive office in Nashville, TN, the company employs around 18,700 staff across 520 care centers in 37 states and the District of Columbia. Founded in 1982, Amedisys is dedicated to providing quality, clinically-distinctive care to more than 469,000 patients annually, with over 10.6 million visits each year.
Amedisys operates across four key segments: Home Health, Hospice, High Acuity Care, and Personal Care. The Home Health segment offers skilled nursing, therapy, and aid services directly in patients' homes, while the Hospice segment provides end-of-life care to terminally ill patients. The High Acuity Care segment delivers critical inpatient care elements at home, and the Personal Care segment, which was divested in March 2023, offered assistance with daily living activities.
Amedisys's commitment to high-quality care is underpinned by its comprehensive coordination with healthcare providers and personalized care plans tailored to each patient's unique needs. With a strong network involving more than 3,000 hospitals and 110,000 physicians nationwide, Amedisys is a trusted partner in post-acute care.
Recent notable achievements include a merger agreement with UnitedHealth Group, aimed at enhancing patient care through integrated services. Financially, Amedisys reported a net service revenue increase to $571.4 million for Q1 2024, reflecting a robust service demand despite divesting the Personal Care segment.
Additionally, Amedisys is actively involved in advancing healthcare technology. The company has partnered with Patient Choice Laboratories to incorporate advanced molecular testing, enhancing infection diagnosis and patient outcomes. This innovation underscores Amedisys’s commitment to leveraging cutting-edge technology to improve patient care.
For stakeholders, Amedisys remains a prominent figure in the home healthcare industry, constantly adapting and growing to meet the increasing needs of its patient population. The company's strategic partnerships and advancements in healthcare technology position it well for sustained growth and improved patient outcomes.
Amedisys, a provider of home health, hospice, and personal care, announced that CEO Paul B. Kusserow and COO Scott Ginn will present at the Bank of America Securities Home Care Conference on December 6, 2022, at 9 a.m. ET. The presentation will be available via live webcast on the company's investor relations website.
Amedisys, founded in 1982 and headquartered in Baton Rouge, LA, delivers care to over 445,000 patients annually, with approximately 21,000 employees and 547 care centers across 36 states.
Amedisys, Inc. (NASDAQ: AMED) has appointed Scott Ginn as Acting Chief Operating Officer, effective immediately. Ginn, who has been with the company since 2007, will retain his role as Chief Financial Officer while overseeing home health, hospice, and personal care operations. Chairman and CEO Paul Kusserow expressed confidence in Ginn's leadership to deliver strong results. Amedisys is a leading provider of home healthcare services, catering to over 445,000 patients annually across 36 states, showcasing its commitment to high-quality care.
Amedisys, Inc. (NASDAQ: AMED) announced a leadership change on November 17, 2022, with CEO Chris Gerard departing and Paul Kusserow, Chair of the Board, stepping in as interim CEO. The company confirmed its full-year guidance, indicating it is on track to meet previously released targets. Amedisys provides various healthcare services at home, partnering with over 3,000 hospitals and 90,000 physicians, serving more than 445,000 patients annually.
Amedisys (NASDAQ: AMED) announced on November 17, 2022, that President and CEO Chris Gerard has left the company. Paul Kusserow, former CEO, will take over as Chairman and CEO until a new leader is selected. The board expressed confidence in Kusserow's ability to drive profitable growth and innovation. The company is initiating an executive search for Gerard's replacement. Amedisys is a leading home healthcare provider, servicing over 445,000 patients annually with approximately 21,000 employees across 36 states.
Amedisys, Inc. (NASDAQ: AMED) responded to the CY 2023 Home Health Final Rule released by CMS, stating it is an improvement over prior proposals. The rule includes a 4.0% market basket update, the highest for home health agencies, and reduces behavioral adjustment cuts by half. Amedisys acknowledges the support from Congress and advocates in the healthcare community while expressing ongoing concerns about the CMS's budget neutrality methodology. The company remains committed to working with stakeholders to ensure sustainable Medicare payment policies for home health services.
Amedisys, Inc. (NASDAQ: AMED) reported Q3 2022 financial results with a net service revenue increase to $558 million, but net income dropped to $25.6 million from $45 million in Q3 2021. Adjusted EBITDA also fell to $61.5 million. Year-to-date results showed a revenue rise to $1.66 billion, yet net income decreased to $86.9 million compared to $175 million in 2021. The company anticipates adjusted net service revenue between $2.224 billion and $2.230 billion for 2022. Amedisys is focused on partnerships to drive growth despite facing operational challenges.
Amedisys, Inc. (NASDAQ: AMED) will announce its third-quarter results on October 26, 2022, after market closure. The investor call is scheduled for 11:00 a.m. ET on October 27, 2022. Interested participants can join by calling either (877) 524-8416 or (412) 902-1028. A replay will be available until November 27, 2022. Amedisys specializes in home health, hospice, personal care, and high-acuity services, serving over 445,000 patients annually across 547 care centers in 36 states. For more details, visit the company's investor relations website.
Amedisys (NASDAQ: AMED) has partnered with the University of Arkansas for Medical Sciences (UAMS) and Contessa to introduce a comprehensive care-at-home program in Central Arkansas. This first-of-its-kind initiative includes Recovery Care, Rehabilitation Care, and Palliative Care at Home, allowing patients to receive essential medical services in their homes. The program aims to improve patient outcomes, increase access to care, and reduce overall healthcare costs. Services are set to begin later this year, boosting the region's healthcare offerings.
Amedisys, a leader in home health and hospice care, appointed Adam Holton as Chief People Officer on September 27, 2022. With over 20 years of HR experience, Holton aims to enhance talent acquisition and employee engagement strategies essential for the company's growth. Previously the Chief Human Resources Officer at Numotion and CHS, he brings extensive knowledge from various leadership roles, including his service as a Marine Corps Infantry Officer. Amedisys emphasizes that investing in human capital is vital for delivering high-quality patient care, especially in a competitive market.
FAQ
What is the current stock price of Amedisys (AMED)?
What is the market cap of Amedisys (AMED)?
What services does Amedisys Inc. provide?
Where is Amedisys Inc. headquartered?
How many employees does Amedisys have?
What is the scope of Amedisys's operations?
How many patients does Amedisys serve annually?
What recent merger has Amedisys entered into?
What recent technological advancement has Amedisys incorporated?
What was Amedisys's net service revenue for Q1 2024?
How does Amedisys coordinate patient care?
What was the Personal Care segment of Amedisys?
